loading
Regeneron Pharmaceuticals Inc stock is traded at $751.95, with a volume of 487.19K. It is down -2.41% in the last 24 hours and down -4.12% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$771.25
Open:
$765.15
24h Volume:
487.19K
Relative Volume:
0.50
Market Cap:
$79.06B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
18.00
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
+0.44%
1M Performance:
-4.12%
6M Performance:
+34.73%
1Y Performance:
+9.66%
1-Day Range:
Value
$747.57
$766.99
1-Week Range:
Value
$747.30
$776.25
52-Week Range:
Value
$476.49
$821.11

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Name
Regeneron Pharmaceuticals Inc
Name
Phone
(914) 847-7000
Name
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Employee
15,207
Name
Twitter
@regeneron
Name
Next Earnings Date
2025-08-01
Name
Latest SEC Filings
Name
REGN's Discussions on Twitter

Compare REGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
752.25 81.06B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.00 120.31B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
ARGX
Argen X Se Adr
846.37 53.49B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
349.51 46.87B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
349.15 37.20B 4.98B 69.59M 525.67M 0.5197

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-07-26 Upgrade BofA Securities Underperform → Buy
Dec-03-25 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-24-25 Initiated HSBC Securities Buy
Nov-24-25 Resumed Truist Buy
Nov-13-25 Initiated Scotiabank Sector Perform
Aug-14-25 Initiated Rothschild & Co Redburn Buy
Jun-30-25 Downgrade Argus Buy → Hold
May-30-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
May-30-25 Downgrade Wells Fargo Overweight → Equal Weight
May-14-25 Upgrade Citigroup Neutral → Buy
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Feb-05-25 Upgrade Leerink Partners Market Perform → Outperform
Jan-16-25 Downgrade UBS Buy → Neutral
Dec-10-24 Resumed BofA Securities Underperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Neutral
Sep-24-24 Downgrade Leerink Partners Outperform → Market Perform
Mar-12-24 Initiated Bernstein Outperform
Jan-12-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Nov-03-23 Upgrade Raymond James Mkt Perform → Outperform
Aug-21-23 Upgrade Canaccord Genuity Hold → Buy
Aug-21-23 Reiterated Oppenheimer Perform
Jun-28-23 Downgrade Canaccord Genuity Buy → Hold
Mar-27-23 Upgrade SVB Securities Market Perform → Outperform
Mar-24-23 Upgrade Jefferies Hold → Buy
Mar-23-23 Upgrade Raymond James Underperform → Mkt Perform
Jan-30-23 Upgrade Cowen Market Perform → Outperform
Jan-20-23 Upgrade JP Morgan Neutral → Overweight
Oct-26-22 Downgrade Raymond James Mkt Perform → Underperform
Oct-17-22 Downgrade Evercore ISI Outperform → In-line
Sep-09-22 Upgrade Jefferies Underperform → Hold
Sep-09-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-25-22 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-06-22 Initiated Jefferies Underperform
May-23-22 Initiated SVB Leerink Outperform
Jan-05-22 Downgrade BofA Securities Neutral → Underperform
Jan-03-22 Upgrade Bernstein Mkt Perform → Outperform
Dec-15-21 Downgrade Bernstein Outperform → Mkt Perform
Dec-09-21 Resumed Wells Fargo Overweight
Dec-07-21 Resumed Cowen Market Perform
Dec-06-21 Initiated Goldman Buy
Nov-19-21 Resumed BMO Capital Markets Outperform
Nov-05-21 Downgrade The Benchmark Company Buy → Hold
Jun-29-21 Initiated H.C. Wainwright Buy
Jan-25-21 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-13-21 Upgrade The Benchmark Company Hold → Buy
Jan-08-21 Upgrade Citigroup Neutral → Buy
Oct-05-20 Upgrade Cantor Fitzgerald Neutral → Overweight
Aug-20-20 Downgrade The Benchmark Company Buy → Hold
Jul-09-20 Upgrade SunTrust Hold → Buy
May-26-20 Upgrade Wells Fargo Equal Weight → Overweight
Apr-28-20 Downgrade Citigroup Buy → Neutral
Apr-17-20 Upgrade The Benchmark Company Hold → Buy
Apr-08-20 Initiated The Benchmark Company Hold
Mar-31-20 Initiated Wolfe Research Peer Perform
Feb-27-20 Initiated Barclays Overweight
Feb-26-20 Upgrade Canaccord Genuity Hold → Buy
Feb-26-20 Downgrade Robert W. Baird Outperform → Neutral
Feb-25-20 Upgrade Jefferies Hold → Buy
Feb-11-20 Upgrade Argus Hold → Buy
Dec-24-19 Initiated Raymond James Mkt Perform
Dec-16-19 Downgrade Evercore ISI Outperform → In-line
Dec-13-19 Upgrade Credit Suisse Neutral → Outperform
Nov-12-19 Initiated SunTrust Hold
Nov-07-19 Upgrade Citigroup Neutral → Buy
Oct-17-19 Resumed BofA/Merrill Neutral
Sep-23-19 Upgrade Guggenheim Neutral → Buy
View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

pulisher
11:29 AM

NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Finviz

11:29 AM
pulisher
09:11 AM

Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? - TradingView

09:11 AM
pulisher
06:30 AM

Federated Hermes Inc. Has $132.81 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

06:30 AM
pulisher
06:29 AM

Cambiar Investors LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

06:29 AM
pulisher
05:31 AM

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cullen Frost Bankers Inc. - MarketBeat

05:31 AM
pulisher
Jan 27, 2026

Eylea HD Approval And STEM Focus Shape Regeneron’s Growth Outlook - simplywall.st

Jan 27, 2026
pulisher
Jan 27, 2026

Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR - GlobeNewswire Inc.

Jan 27, 2026
pulisher
Jan 27, 2026

Regeneron (REGN) Posted Solid Quarterly Results, Eyes 2026 Pipeline Catalysts - Insider Monkey

Jan 27, 2026
pulisher
Jan 27, 2026

Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Regeneron (REGN) - The Globe and Mail

Jan 27, 2026
pulisher
Jan 27, 2026

Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug - Seeking Alpha

Jan 27, 2026
pulisher
Jan 27, 2026

Lbp Am Sa Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jan 27, 2026
pulisher
Jan 27, 2026

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $916 From $911, Maintains Outperform Rating - marketscreener.com

Jan 27, 2026
pulisher
Jan 27, 2026

Compass Wealth Management LLC Buys Shares of 3,634 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jan 27, 2026
pulisher
Jan 27, 2026

General American Investors Co. Inc. Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jan 27, 2026
pulisher
Jan 26, 2026

Sovran Advisors LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jan 26, 2026
pulisher
Jan 26, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat

Jan 26, 2026
pulisher
Jan 26, 2026

Regeneron Pharmaceuticals (REGN) Valuation Check After Eylea HD Approval And Ongoing Dupixent Momentum - simplywall.st

Jan 26, 2026
pulisher
Jan 25, 2026

Y Intercept Hong Kong Ltd Sells 24,556 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jan 25, 2026
pulisher
Jan 25, 2026

Stoneridge Investment Partners LLC Buys Shares of 2,360 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jan 25, 2026
pulisher
Jan 25, 2026

Resona Asset Management Co. Ltd. Sells 5,371 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jan 25, 2026
pulisher
Jan 25, 2026

Teacher Retirement System of Texas Sells 2,558 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jan 25, 2026
pulisher
Jan 24, 2026

What Regeneron Pharmaceuticals (REGN)'s Eylea HD Progress and STEM Investment Push Means For Shareholders - simplywall.st

Jan 24, 2026
pulisher
Jan 24, 2026

Oxbow Advisors LLC Takes $2.95 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jan 24, 2026
pulisher
Jan 24, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat

Jan 24, 2026
pulisher
Jan 23, 2026

Regeneron: Q4 Earnings PreviewWhy I'm Expecting A Beat And Strong 2026 (NASDAQ:REGN) - Seeking Alpha

Jan 23, 2026
pulisher
Jan 23, 2026

Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz

Jan 23, 2026
pulisher
Jan 23, 2026

Big Pharma shops Chinese biotechs to stock GLP-1 pipelines - Pharma Voice

Jan 23, 2026
pulisher
Jan 23, 2026

The Truth About Regeneron Pharmaceuticals: Why Wall Street Can’t Stop Watching REGN - AD HOC NEWS

Jan 23, 2026
pulisher
Jan 23, 2026

How Regeneron’s Broader Biologics Pipeline And Capital Return Focus At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story - Yahoo Finance

Jan 23, 2026
pulisher
Jan 23, 2026

Is Regeneron Pharmaceuticals (REGN) Still Attractive After Recent Share Price Weakness? - simplywall.st

Jan 23, 2026
pulisher
Jan 23, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Jan 23, 2026
pulisher
Jan 23, 2026

Regeneron Pharmaceuticals (REGN) Projected to Post Quarterly Earnings on Friday - MarketBeat

Jan 23, 2026
pulisher
Jan 22, 2026

Bi Specific Antibodies Therapy Market Is Booming Worldwide | AbbVie • Regeneron Pharmaceuticals • Pfizer - openPR.com

Jan 22, 2026
pulisher
Jan 22, 2026

2 Healthcare Stocks Poised for a Comeback in 2026 - Finviz

Jan 22, 2026
pulisher
Jan 22, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $875.00 at Evercore ISI - MarketBeat

Jan 22, 2026
pulisher
Jan 22, 2026

REGN: Evercore ISI Group Raises Price Target to $875, Maintains Outperform Rating | REGN Stock News - GuruFocus

Jan 22, 2026
pulisher
Jan 22, 2026

Analysts Crow About Potential Of Corvus Pill To Beat Dupixent - Citeline News & Insights

Jan 22, 2026
pulisher
Jan 22, 2026

Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jan 22, 2026
pulisher
Jan 21, 2026

Regeneron Faces Neurology Leadership Shift As Investors Weigh Pipeline Execution - simplywall.st

Jan 21, 2026
pulisher
Jan 21, 2026

Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer - citybiz

Jan 21, 2026
pulisher
Jan 21, 2026

2 Westchester County Teens Among 40 Regeneron Science Talent Search 2026 Finalists - Patch

Jan 21, 2026
pulisher
Jan 21, 2026

40 teen scientists vie for $1.8M at Regeneron talent search - Stock Titan

Jan 21, 2026
pulisher
Jan 21, 2026

58,906 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Rakuten Investment Management Inc. - MarketBeat

Jan 21, 2026
pulisher
Jan 21, 2026

Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer - manilatimes.net

Jan 21, 2026
pulisher
Jan 20, 2026

Seizert Capital Partners LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jan 20, 2026
pulisher
Jan 20, 2026

(REGN) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Jan 20, 2026
pulisher
Jan 20, 2026

Should You Be Excited for Regeneron (REGN)? - Insider Monkey

Jan 20, 2026
pulisher
Jan 20, 2026

A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum - Yahoo Finance

Jan 20, 2026
pulisher
Jan 20, 2026

Allstate Corp Makes New $2.12 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jan 20, 2026
pulisher
Jan 20, 2026

Expansion wave in Saratoga County, New York: Regeneron, GlobalFoundries, Soleno, LISSMAC and more - The Business Journals

Jan 20, 2026
pulisher
Jan 19, 2026

Third retinal indication for Eylea 8mg approved in Europe - The Pharma Letter

Jan 19, 2026

Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$846.30
price down icon 2.10%
$349.21
price down icon 1.56%
biotechnology ONC
$348.99
price up icon 3.74%
$476.69
price up icon 0.57%
$157.08
price down icon 3.31%
Cap:     |  Volume (24h):